Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
Ligand (Nasdaq: LGND) announced that CEO Todd Davis and CFO Tavo Espinoza will participate in a virtual fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 10:00 a.m. Eastern Time.
Management is also scheduled for one-on-one investor meetings during the conference; investors should contact their Oppenheimer representative to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction – LGND
In the Feb 4 session, LGND declined 0.26%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 09 | Investor Day, guidance | Positive | +0.6% | Introduced 2026 revenue and EPS guidance with long‑term royalty outlook. |
| Nov 06 | Earnings beat, guidance | Positive | +9.4% | Reported strong Q3 2025 results and raised 2025 guidance metrics. |
| Oct 30 | Investor conferences | Neutral | +2.3% | Announced participation in three November 2025 healthcare investor conferences. |
| Oct 23 | Earnings date notice | Neutral | -0.2% | Set date and call details for reporting Q3 2025 financial results. |
| Oct 16 | Investor Day announcement | Neutral | -1.4% | Planned Dec 9, 2025 Investor Day covering strategy and royalty portfolio. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Operational and guidance updates have generally seen positive or modestly positive price reactions, while routine conference announcements have produced small moves in either direction.
Over the past few months, Ligand has combined strong fundamentals with active investor outreach. The Q3 2025 earnings report on Nov 6, 2025 showed sharply higher revenue and EPS with raised guidance, and the 10-Q confirmed robust royalty growth and a larger cash position. The company then promoted an Investor Day on Dec 9, 2025 and later introduced detailed 2026 guidance and a five‑year royalty outlook. Multiple conference appearances in October and November 2025 underline a consistent strategy of engaging investors through events like the newly announced Oppenheimer conference participation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which will be held virtually, on February 25, 2026 at 10:00 a.m. Eastern Time.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during the conference. Investors interested in arranging one-on-one meetings should contact their Oppenheimer representative.
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.
We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
